Capella Bioscience raises $15.5 mln
Capella Bioscience Ltd said Tuesday it closed an 11 million pound ($15.5 million) Series A financing round. Investors include Advent Life Sciences, Medicxi Ventures, and Osage University Partners. London-based Capella is developing monoclonal antibody medicines.
8 March 2016•3 mins read
